Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation
Catharina Schuetz, Manfred Hoenig, Despina Moshous, Christof Weinstock, Martin Castelle, Matthieu Bendavid, Kristin Shimano, Vanessa Tolbert, Ansgar S Schulz, Christopher C Dvorak, Catharina Schuetz, Manfred Hoenig, Despina Moshous, Christof Weinstock, Martin Castelle, Matthieu Bendavid, Kristin Shimano, Vanessa Tolbert, Ansgar S Schulz, Christopher C Dvorak
Abstract
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post-hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune dysregulation including autoimmune cytopenias. We describe an innovative therapy for AIHA refractory to proteasome inhibition. In potentially life-threatening AIHA in the context of HSCT, daratumumab may be an effective rescue therapy.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
© 2018 by The American Society of Hematology.
Figures
Source: PubMed